CK Life Sciences (00775) announces its annual performance, with a net loss attributable to shareholders of HK$187 million, representing an increase of 47.61% year-on-year.

18:45 17/03/2026

Changjiang Life Sciences and Technology (00775) released its performance for the year 2025, with the group achieving revenue of 5.41 billion Hong Kong dollars, a decrease of 2% compared to the previous year. The company's shareholders' equity should account for a loss of 187 million Hong Kong dollars, an increase of 47.61% compared to the previous year; with a loss per share of 1.94 Hong Kong cents.

CK Life Sciences (00775) announced its performance for the year 2025, with the group achieving revenue of HK$5.41 billion, a decrease of 2% year-on-year. The company's shareholders' equity loss amounted to HK$187 million, an increase of 47.61% year-on-year. The loss per share was HK$0.194. The shareholders' equity loss for the year 2025 increased by HK$60.20 million compared to 2024, reflecting an increase in research and development expenses of HK$66.50 million, as well as several non-cash special items and one-off projects, including a significant decrease in the valuation of the vineyard asset portfolio, several provisions, and transaction gains from the subsidiary company Polynoma's dealings with the Nasdaq-listed company TransCode Therapeutics (NAZ).

CHENMING PAPER (01812) A-share stock price abnormal movement, there is no significant undisclosed major issue that should be disclosed.

ZYLOXTB (02190) intends to issue a final dividend of 0.22 yuan per share.

On March 17th, NetEase Music (09899) spent 14.996 million Hong Kong dollars to repurchase 99,500 shares.

CHENMING PAPER (01812) A-share stock price abnormal movement, there is no significant undisclosed major issue that should be disclosed.

ZYLOXTB (02190) intends to issue a final dividend of 0.22 yuan per share.

On March 17th, NetEase Music (09899) spent 14.996 million Hong Kong dollars to repurchase 99,500 shares.